APO Research
Talk to an analyst

APO RESEARCH · REPORT

Postmenopausal Osteoporosis Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Postmenopausal Osteoporosis Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

20 December 2025197 pages

Choose your research edition.

Industry ResearchPostmenopausal Osteoporosis Drugs Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Postmenopausal Osteoporosis Drugs Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Postmenopausal Osteoporosis Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Postmenopausal Osteoporosis Drugs Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Postmenopausal Osteoporosis Drugs Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Postmenopausal Osteoporosis Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Postmenopausal Osteoporosis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Postmenopausal Osteoporosis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Postmenopausal Osteoporosis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Postmenopausal Osteoporosis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Postmenopausal Osteoporosis Drugs include Allergan, Amgen Astellas Biopharm, Deltanoid Pharmaceuticals, Noven, Novo Nordisk, Osteologix, PhytoHealth, Radius Health and Tarsa Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Postmenopausal Osteoporosis Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Postmenopausal Osteoporosis Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Postmenopausal Osteoporosis Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Postmenopausal Osteoporosis Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Postmenopausal Osteoporosis Drugs Segment by Company

Allergan

Amgen Astellas Biopharm

Deltanoid Pharmaceuticals

Noven

Novo Nordisk

Osteologix

PhytoHealth

Radius Health

Tarsa Therapeutics

Amgen

Pfizer

Eli Lilly

Merck

Novartis

Postmenopausal Osteoporosis Drugs Segment by Type

Antiresorptive Medications

Anabolic Medications

Postmenopausal Osteoporosis Drugs Segment by Application

Hospital

Pharmacy

Other

Postmenopausal Osteoporosis Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Postmenopausal Osteoporosis Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Postmenopausal Osteoporosis Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Postmenopausal Osteoporosis Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Postmenopausal Osteoporosis Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Postmenopausal Osteoporosis Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Postmenopausal Osteoporosis Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Postmenopausal Osteoporosis Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Postmenopausal Osteoporosis Drugs Industry Trends Table 2. Postmenopausal Osteoporosis Drugs Industry Drivers Table 3. Postmenopausal Osteoporosis Drugs Industry Opportunities and Challenges Table 4. Postmenopausal Osteoporosis Drugs Industry Restraints Table 5. Global Postmenopausal Osteoporosis Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Postmenopausal Osteoporosis Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Postmenopausal Osteoporosis Drugs Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Postmenopausal Osteoporosis Drugs Sales Market Share by Manufacturers Table 9. Global Postmenopausal Osteoporosis Drugs Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Postmenopausal Osteoporosis Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Postmenopausal Osteoporosis Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Postmenopausal Osteoporosis Drugs Manufacturers, Product Type & Application Table 13. Global Postmenopausal Osteoporosis Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Postmenopausal Osteoporosis Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Antiresorptive Medications Table 17. Major Manufacturers of Anabolic Medications Table 18. Global Postmenopausal Osteoporosis Drugs Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Postmenopausal Osteoporosis Drugs Sales by Type (2021-2026) & (K Units) Table 20. Global Postmenopausal Osteoporosis Drugs Sales by Type (2027-2032) & (K Units) Table 21. Global Postmenopausal Osteoporosis Drugs Sales Market Share by Type (2021-2026) Table 22. Global Postmenopausal Osteoporosis Drugs Sales Market Share by Type (2027-2032) Table 23. Global Postmenopausal Osteoporosis Drugs Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Postmenopausal Osteoporosis Drugs Revenue by Type (2021-2026) & (K Units) Table 25. Global Postmenopausal Osteoporosis Drugs Revenue by Type (2027-2032) & (K Units) Table 26. Global Postmenopausal Osteoporosis Drugs Revenue Market Share by Type (2021-2026) Table 27. Global Postmenopausal Osteoporosis Drugs Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Hospital Table 29. Major Manufacturers of Pharmacy Table 30. Major Manufacturers of Other Table 31. Global Postmenopausal Osteoporosis Drugs Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Postmenopausal Osteoporosis Drugs Sales by Application (2021-2026) & (K Units) Table 33. Global Postmenopausal Osteoporosis Drugs Sales by Application (2027-2032) & (K Units) Table 34. Global Postmenopausal Osteoporosis Drugs Sales Market Share by Application (2021-2026) Table 35. Global Postmenopausal Osteoporosis Drugs Sales Market Share by Application (2027-2032) Table 36. Global Postmenopausal Osteoporosis Drugs Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Postmenopausal Osteoporosis Drugs Revenue by Application (2021-2026) & (K Units) Table 38. Global Postmenopausal Osteoporosis Drugs Revenue by Application (2027-2032) & (K Units) Table 39. Global Postmenopausal Osteoporosis Drugs Revenue Market Share by Application (2021-2026) Table 40. Global Postmenopausal Osteoporosis Drugs Revenue Market Share by Application (2027-2032) Table 41. Global Postmenopausal Osteoporosis Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Postmenopausal Osteoporosis Drugs Sales by Region (2021-2026) & (K Units) Table 43. Global Postmenopausal Osteoporosis Drugs Sales Market Share by Region (2021-2026) Table 44. Global Postmenopausal Osteoporosis Drugs Sales Forecasted by Region (2027-2032) & (K Units) Table 45. Global Postmenopausal Osteoporosis Drugs Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Postmenopausal Osteoporosis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 47. North America Postmenopausal Osteoporosis Drugs Sales by Country (2021-2026) & (K Units) Table 48. North America Postmenopausal Osteoporosis Drugs Sales by Country (2027-2032) & (K Units) Table 49. Europe Postmenopausal Osteoporosis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. Europe Postmenopausal Osteoporosis Drugs Sales by Country (2021-2026) & (K Units) Table 51. Europe Postmenopausal Osteoporosis Drugs Sales by Country (2027-2032) & (K Units) Table 52. Asia Pacific Postmenopausal Osteoporosis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Asia Pacific Postmenopausal Osteoporosis Drugs Sales by Country (2021-2026) & (K Units) Table 54. Asia Pacific Postmenopausal Osteoporosis Drugs Sales by Country (2027-2032) & (K Units) Table 55. South America, Middle East and Africa Postmenopausal Osteoporosis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. South America, Middle East and Africa Postmenopausal Osteoporosis Drugs Sales by Country (2021-2026) & (K Units) Table 57. South America, Middle East and Africa Postmenopausal Osteoporosis Drugs Sales by Country (2027-2032) & (K Units) Table 58. Global Postmenopausal Osteoporosis Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Postmenopausal Osteoporosis Drugs Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Postmenopausal Osteoporosis Drugs Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Postmenopausal Osteoporosis Drugs Revenue Market Share by Region (2021-2026) Table 62. Global Postmenopausal Osteoporosis Drugs Revenue Market Share by Region (2027-2032) Table 63. Allergan Company Information Table 64. Allergan Business Overview Table 65. Allergan Postmenopausal Osteoporosis Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Allergan Postmenopausal Osteoporosis Drugs Product Portfolio Table 67. Allergan Recent Development Table 68. Amgen Astellas Biopharm Company Information Table 69. Amgen Astellas Biopharm Business Overview Table 70. Amgen Astellas Biopharm Postmenopausal Osteoporosis Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Amgen Astellas Biopharm Postmenopausal Osteoporosis Drugs Product Portfolio Table 72. Amgen Astellas Biopharm Recent Development Table 73. Deltanoid Pharmaceuticals Company Information Table 74. Deltanoid Pharmaceuticals Business Overview Table 75. Deltanoid Pharmaceuticals Postmenopausal Osteoporosis Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Deltanoid Pharmaceuticals Postmenopausal Osteoporosis Drugs Product Portfolio Table 77. Deltanoid Pharmaceuticals Recent Development Table 78. Noven Company Information Table 79. Noven Business Overview Table 80. Noven Postmenopausal Osteoporosis Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Noven Postmenopausal Osteoporosis Drugs Product Portfolio Table 82. Noven Recent Development Table 83. Novo Nordisk Company Information Table 84. Novo Nordisk Business Overview Table 85. Novo Nordisk Postmenopausal Osteoporosis Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Novo Nordisk Postmenopausal Osteoporosis Drugs Product Portfolio Table 87. Novo Nordisk Recent Development Table 88. Osteologix Company Information Table 89. Osteologix Business Overview Table 90. Osteologix Postmenopausal Osteoporosis Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Osteologix Postmenopausal Osteoporosis Drugs Product Portfolio Table 92. Osteologix Recent Development Table 93. PhytoHealth Company Information Table 94. PhytoHealth Business Overview Table 95. PhytoHealth Postmenopausal Osteoporosis Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. PhytoHealth Postmenopausal Osteoporosis Drugs Product Portfolio Table 97. PhytoHealth Recent Development Table 98. Radius Health Company Information Table 99. Radius Health Business Overview Table 100. Radius Health Postmenopausal Osteoporosis Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Radius Health Postmenopausal Osteoporosis Drugs Product Portfolio Table 102. Radius Health Recent Development Table 103. Tarsa Therapeutics Company Information Table 104. Tarsa Therapeutics Business Overview Table 105. Tarsa Therapeutics Postmenopausal Osteoporosis Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Tarsa Therapeutics Postmenopausal Osteoporosis Drugs Product Portfolio Table 107. Tarsa Therapeutics Recent Development Table 108. Amgen Company Information Table 109. Amgen Business Overview Table 110. Amgen Postmenopausal Osteoporosis Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Amgen Postmenopausal Osteoporosis Drugs Product Portfolio Table 112. Amgen Recent Development Table 113. Pfizer Company Information Table 114. Pfizer Business Overview Table 115. Pfizer Postmenopausal Osteoporosis Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Pfizer Postmenopausal Osteoporosis Drugs Product Portfolio Table 117. Pfizer Recent Development Table 118. Eli Lilly Company Information Table 119. Eli Lilly Business Overview Table 120. Eli Lilly Postmenopausal Osteoporosis Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. Eli Lilly Postmenopausal Osteoporosis Drugs Product Portfolio Table 122. Eli Lilly Recent Development Table 123. Merck Company Information Table 124. Merck Business Overview Table 125. Merck Postmenopausal Osteoporosis Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 126. Merck Postmenopausal Osteoporosis Drugs Product Portfolio Table 127. Merck Recent Development Table 128. Novartis Company Information Table 129. Novartis Business Overview Table 130. Novartis Postmenopausal Osteoporosis Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 131. Novartis Postmenopausal Osteoporosis Drugs Product Portfolio Table 132. Novartis Recent Development Table 133. Key Raw Materials Table 134. Raw Materials Key Suppliers Table 135. Postmenopausal Osteoporosis Drugs Distributors List Table 136. Postmenopausal Osteoporosis Drugs Customers List Table 137. Research Programs/Design for This Report Table 138. Authors List of This Report Table 139. Secondary Sources Table 140. Primary Sources List of Figures Figure 1. Postmenopausal Osteoporosis Drugs Product Image Figure 2. Global Postmenopausal Osteoporosis Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Postmenopausal Osteoporosis Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Postmenopausal Osteoporosis Drugs Sales (2021-2032) & (K Units) Figure 5. Global Postmenopausal Osteoporosis Drugs Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Postmenopausal Osteoporosis Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Antiresorptive Medications Image Figure 9. Anabolic Medications Image Figure 10. Global Postmenopausal Osteoporosis Drugs Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Postmenopausal Osteoporosis Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Postmenopausal Osteoporosis Drugs Sales Market Share by Type (2021-2032) Figure 13. Global Postmenopausal Osteoporosis Drugs Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Postmenopausal Osteoporosis Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Postmenopausal Osteoporosis Drugs Revenue Market Share by Type (2021-2032) Figure 16. Hospital Image Figure 17. Pharmacy Image Figure 18. Other Image Figure 19. Global Postmenopausal Osteoporosis Drugs Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Postmenopausal Osteoporosis Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Postmenopausal Osteoporosis Drugs Sales Market Share by Application (2021-2032) Figure 22. Global Postmenopausal Osteoporosis Drugs Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Postmenopausal Osteoporosis Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Postmenopausal Osteoporosis Drugs Revenue Market Share by Application (2021-2032) Figure 25. North America Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 26. North America Postmenopausal Osteoporosis Drugs Sales Market Share by Country (2021-2032) Figure 27. U.S. Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 28. Canada Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Mexico Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Europe Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Postmenopausal Osteoporosis Drugs Sales Market Share by Country (2021-2032) Figure 32. Germany Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 33. France Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 34. U.K. Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Italy Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Netherlands Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Asia Pacific Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Postmenopausal Osteoporosis Drugs Sales Market Share by Country (2021-2032) Figure 39. China Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Japan Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 41. South Korea Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Southeast Asia Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 43. India Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Australia Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South America, Middle East and Africa Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Postmenopausal Osteoporosis Drugs Sales Market Share by Country (2021-2032) Figure 47. Brazil Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South Africa Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Saudi Arabia Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Turkey Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Argentina Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 52. UAE Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Egypt Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Chile Postmenopausal Osteoporosis Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Global Postmenopausal Osteoporosis Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Postmenopausal Osteoporosis Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Postmenopausal Osteoporosis Drugs Revenue (2021-2032) & (US$ Million) Figure 58. North America Postmenopausal Osteoporosis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Postmenopausal Osteoporosis Drugs Revenue (2021-2032) & (US$ Million) Figure 60. Europe Postmenopausal Osteoporosis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Postmenopausal Osteoporosis Drugs Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Postmenopausal Osteoporosis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Postmenopausal Osteoporosis Drugs Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Postmenopausal Osteoporosis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Postmenopausal Osteoporosis Drugs Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Postmenopausal Osteoporosis Drugs Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Antiresorptive Medications
  • Anabolic Medications
Applications
  • Hospital
  • Pharmacy
  • Other
Companies covered
  • Allergan
  • Amgen Astellas Biopharm
  • Deltanoid Pharmaceuticals
  • Noven
  • Novo Nordisk
  • Osteologix
  • PhytoHealth
  • Radius Health
  • Tarsa Therapeutics
  • Amgen
  • Pfizer
  • Eli Lilly
  • Merck
  • Novartis

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Postmenopausal Osteoporosis Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Postmenopausal Osteoporosis Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Postmenopausal Osteoporosis Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Postmenopausal Osteoporosis Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Postmenopausal Osteoporosis Drugs Market Dynamics
  1. 2.1 Postmenopausal Osteoporosis Drugs Industry Trends
  2. 2.2 Postmenopausal Osteoporosis Drugs Industry Drivers
  3. 2.3 Postmenopausal Osteoporosis Drugs Industry Opportunities and Challenges
  4. 2.4 Postmenopausal Osteoporosis Drugs Industry Restraints
3 Postmenopausal Osteoporosis Drugs Market by Manufacturers
  1. 3.1 Global Postmenopausal Osteoporosis Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Postmenopausal Osteoporosis Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Postmenopausal Osteoporosis Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Postmenopausal Osteoporosis Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Postmenopausal Osteoporosis Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Postmenopausal Osteoporosis Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Postmenopausal Osteoporosis Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Postmenopausal Osteoporosis Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Postmenopausal Osteoporosis Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Postmenopausal Osteoporosis Drugs Tier 1, Tier 2, and Tier 3
4 Postmenopausal Osteoporosis Drugs Market by Type
  1. 4.1 Postmenopausal Osteoporosis Drugs Type Introduction
  2. 4.1.1 Antiresorptive Medications
  3. 4.1.2 Anabolic Medications
  4. 4.2 Global Postmenopausal Osteoporosis Drugs Sales by Type
  5. 4.2.1 Global Postmenopausal Osteoporosis Drugs Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Postmenopausal Osteoporosis Drugs Sales by Type (2021-2032)
  7. 4.2.3 Global Postmenopausal Osteoporosis Drugs Sales Market Share by Type (2021-2032)
  8. 4.3 Global Postmenopausal Osteoporosis Drugs Revenue by Type
  9. 4.3.1 Global Postmenopausal Osteoporosis Drugs Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Postmenopausal Osteoporosis Drugs Revenue by Type (2021-2032)
  11. 4.3.3 Global Postmenopausal Osteoporosis Drugs Revenue Market Share by Type (2021-2032)
5 Postmenopausal Osteoporosis Drugs Market by Application
  1. 5.1 Postmenopausal Osteoporosis Drugs Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Postmenopausal Osteoporosis Drugs Sales by Application
  6. 5.2.1 Global Postmenopausal Osteoporosis Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Postmenopausal Osteoporosis Drugs Sales by Application (2021-2032)
  8. 5.2.3 Global Postmenopausal Osteoporosis Drugs Sales Market Share by Application (2021-2032)
  9. 5.3 Global Postmenopausal Osteoporosis Drugs Revenue by Application
  10. 5.3.1 Global Postmenopausal Osteoporosis Drugs Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Postmenopausal Osteoporosis Drugs Revenue by Application (2021-2032)
  12. 5.3.3 Global Postmenopausal Osteoporosis Drugs Revenue Market Share by Application (2021-2032)
6 Global Postmenopausal Osteoporosis Drugs Sales by Region
  1. 6.1 Global Postmenopausal Osteoporosis Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Postmenopausal Osteoporosis Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Postmenopausal Osteoporosis Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Postmenopausal Osteoporosis Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Postmenopausal Osteoporosis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Postmenopausal Osteoporosis Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Postmenopausal Osteoporosis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Postmenopausal Osteoporosis Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Postmenopausal Osteoporosis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Postmenopausal Osteoporosis Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Postmenopausal Osteoporosis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Postmenopausal Osteoporosis Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Postmenopausal Osteoporosis Drugs Revenue by Region
  1. 7.1 Global Postmenopausal Osteoporosis Drugs Revenue by Region
  2. 7.1.1 Global Postmenopausal Osteoporosis Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Postmenopausal Osteoporosis Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Postmenopausal Osteoporosis Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Postmenopausal Osteoporosis Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Postmenopausal Osteoporosis Drugs Revenue (2021-2032)
  8. 7.2.2 North America Postmenopausal Osteoporosis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Postmenopausal Osteoporosis Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Postmenopausal Osteoporosis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Postmenopausal Osteoporosis Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Postmenopausal Osteoporosis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Postmenopausal Osteoporosis Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Postmenopausal Osteoporosis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Allergan
  2. 8.1.1 Allergan Company Information
  3. 8.1.2 Allergan Business Overview
  4. 8.1.3 Allergan Postmenopausal Osteoporosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Allergan Postmenopausal Osteoporosis Drugs Product Portfolio
  6. 8.1.5 Allergan Recent Developments
  7. 8.2 Amgen Astellas Biopharm
  8. 8.2.1 Amgen Astellas Biopharm Company Information
  9. 8.2.2 Amgen Astellas Biopharm Business Overview
  10. 8.2.3 Amgen Astellas Biopharm Postmenopausal Osteoporosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Amgen Astellas Biopharm Postmenopausal Osteoporosis Drugs Product Portfolio
  12. 8.2.5 Amgen Astellas Biopharm Recent Developments
  13. 8.3 Deltanoid Pharmaceuticals
  14. 8.3.1 Deltanoid Pharmaceuticals Company Information
  15. 8.3.2 Deltanoid Pharmaceuticals Business Overview
  16. 8.3.3 Deltanoid Pharmaceuticals Postmenopausal Osteoporosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Deltanoid Pharmaceuticals Postmenopausal Osteoporosis Drugs Product Portfolio
  18. 8.3.5 Deltanoid Pharmaceuticals Recent Developments
  19. 8.4 Noven
  20. 8.4.1 Noven Company Information
  21. 8.4.2 Noven Business Overview
  22. 8.4.3 Noven Postmenopausal Osteoporosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Noven Postmenopausal Osteoporosis Drugs Product Portfolio
  24. 8.4.5 Noven Recent Developments
  25. 8.5 Novo Nordisk
  26. 8.5.1 Novo Nordisk Company Information
  27. 8.5.2 Novo Nordisk Business Overview
  28. 8.5.3 Novo Nordisk Postmenopausal Osteoporosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Novo Nordisk Postmenopausal Osteoporosis Drugs Product Portfolio
  30. 8.5.5 Novo Nordisk Recent Developments
  31. 8.6 Osteologix
  32. 8.6.1 Osteologix Company Information
  33. 8.6.2 Osteologix Business Overview
  34. 8.6.3 Osteologix Postmenopausal Osteoporosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Osteologix Postmenopausal Osteoporosis Drugs Product Portfolio
  36. 8.6.5 Osteologix Recent Developments
  37. 8.7 PhytoHealth
  38. 8.7.1 PhytoHealth Company Information
  39. 8.7.2 PhytoHealth Business Overview
  40. 8.7.3 PhytoHealth Postmenopausal Osteoporosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 PhytoHealth Postmenopausal Osteoporosis Drugs Product Portfolio
  42. 8.7.5 PhytoHealth Recent Developments
  43. 8.8 Radius Health
  44. 8.8.1 Radius Health Company Information
  45. 8.8.2 Radius Health Business Overview
  46. 8.8.3 Radius Health Postmenopausal Osteoporosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Radius Health Postmenopausal Osteoporosis Drugs Product Portfolio
  48. 8.8.5 Radius Health Recent Developments
  49. 8.9 Tarsa Therapeutics
  50. 8.9.1 Tarsa Therapeutics Company Information
  51. 8.9.2 Tarsa Therapeutics Business Overview
  52. 8.9.3 Tarsa Therapeutics Postmenopausal Osteoporosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Tarsa Therapeutics Postmenopausal Osteoporosis Drugs Product Portfolio
  54. 8.9.5 Tarsa Therapeutics Recent Developments
  55. 8.10 Amgen
  56. 8.10.1 Amgen Company Information
  57. 8.10.2 Amgen Business Overview
  58. 8.10.3 Amgen Postmenopausal Osteoporosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Amgen Postmenopausal Osteoporosis Drugs Product Portfolio
  60. 8.10.5 Amgen Recent Developments
  61. 8.11 Pfizer
  62. 8.11.1 Pfizer Company Information
  63. 8.11.2 Pfizer Business Overview
  64. 8.11.3 Pfizer Postmenopausal Osteoporosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Pfizer Postmenopausal Osteoporosis Drugs Product Portfolio
  66. 8.11.5 Pfizer Recent Developments
  67. 8.12 Eli Lilly
  68. 8.12.1 Eli Lilly Company Information
  69. 8.12.2 Eli Lilly Business Overview
  70. 8.12.3 Eli Lilly Postmenopausal Osteoporosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Eli Lilly Postmenopausal Osteoporosis Drugs Product Portfolio
  72. 8.12.5 Eli Lilly Recent Developments
  73. 8.13 Merck
  74. 8.13.1 Merck Company Information
  75. 8.13.2 Merck Business Overview
  76. 8.13.3 Merck Postmenopausal Osteoporosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Merck Postmenopausal Osteoporosis Drugs Product Portfolio
  78. 8.13.5 Merck Recent Developments
  79. 8.14 Novartis
  80. 8.14.1 Novartis Company Information
  81. 8.14.2 Novartis Business Overview
  82. 8.14.3 Novartis Postmenopausal Osteoporosis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Novartis Postmenopausal Osteoporosis Drugs Product Portfolio
  84. 8.14.5 Novartis Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Postmenopausal Osteoporosis Drugs Value Chain Analysis
  2. 9.1.1 Postmenopausal Osteoporosis Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Postmenopausal Osteoporosis Drugs Production Mode & Process
  6. 9.2 Postmenopausal Osteoporosis Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Postmenopausal Osteoporosis Drugs Distributors
  9. 9.2.3 Postmenopausal Osteoporosis Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst